

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the **“Company”**) pursuant to Rule 13.09(2)(a) of the Rules (the **“Listing Rules”**) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the **“Inside Information Provisions”**).

References are made to (i) the announcement of the Company dated September 13, 2024 in relation to the application for the H share full circulation by the Company; (ii) the announcement of the Company dated December 19, 2024 in relation to the issuance of the Filing Notice by the CSRC for the H share full circulation application of the Company; and (iii) the announcement of the Company dated February 10, 2025 in relation to the grant of listing approval by the Stock Exchange for the implementation of the H Share Full Circulation (collectively, the **“Announcements”**). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board of the Company is pleased to announce that the conversion of 173,641,645 Unlisted Shares into H shares had been completed on February 18, 2025, and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on February 19, 2025.

SHAREHOLDING STRUCTURE

Immediately before and upon completion of the Conversion and the Listing, the share capital structure of the Company is as follows:

Class of shares	Immediately before completion of the Conversion and the Listing		Upon completion of the Conversion and the Listing	
	<i>Number of shares</i>	<i>Approximate percentage %</i>	<i>Number of shares</i>	<i>Approximate percentage %</i>
H shares	192,586,173	51.93	366,227,818	98.76
Unlisted shares	178,249,645	48.07	4,608,000	1.24
Total	370,835,818	100.00	370,835,818	100.00

Note: The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, February 18, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng and Dr. JIANG Mingyu as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying, Mr. HE Chao and Dr. DING Zhao as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.